Clinical trials: Migraines
Migraine, Healthy
Molecular and Functional PET-fMRI Measures of Analgesia in Migraine
The placebo effect is a phenomenon that has experienced major advances of its understanding in the last decade. However, mechanisms of placebo analgesia in chronic pain patients have yet to be compared to healthy subjects.
- Trial name
- NCT01970943
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Migraine
Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)
The purpose of this study is to determine the receptor occupancy (RO) associated with telcagepant (MK-0974) administration based on displacement of [11C]MK-4232 from the CGRP receptors in the brain using PET.
- Trial name
- NCT01315847
- Testing
- telcagepant, [11C]MK-4232
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine, Headache, Episodic Migraine
Occipital Blocks for Acute Migraine
Migraine affects 10-28% of children and adolescents and yet 20-30% of patients are ineffectively treated with current oral and nasal options.
- Trial name
- NCT03526874
- Testing
- Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Children's Hospital of Philadelphia
Migraine Headache
MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.
- Trial name
- NCT00897949
- Testing
- rizatriptan benzoate (MK0462)
- Volunteers
- 1,473 people
- Sponsor
- Organon and Co
Migraine Disorders
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months
The primary objective is to evaluate the safety of long-term treatment with NP101 as assessed by: Subject self-examination skin irritation scores Adverse events Changes in vital signs and ECG parameters The secondary objective is…
- Trial name
- NP101-008 (NCT00792103)
- Testing
- NP101
- Where
- 34 sites in United States
- Volunteers
- 198 people
- Sponsor
- NuPathe Inc.
Chronic Migraine
Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action
The purpose of this study is to understand better the mechanisms of action of calcitonin gene related peptide (CGRP) targeted monoclonal antibodies in migraine prevention.
- Trial name
- NCT04271202
- Testing
- Emgality 120 MG in 1 ML Prefilled Syringe
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Beth Israel Deaconess Medical Center
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SAMURAI (NCT02439320)
- Testing
- Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 92 sites in United States
- Volunteers
- 2,231 people
- Sponsor
- Eli Lilly and Company
Migraine
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with chronic migraine
- Trial name
- NCT02621931
- Testing
- Fremanezumab
- Where
- 273 sites in United States, Canada and 7 more
- Volunteers
- 1,130 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
This study used a single-cohort, 2-treatment arm, parallel-group randomized, double-blind, double-dummy design in adult patients with episodic migraine and chronic migraine, who had to be either naïve or not suitable for or could…
- Trial name
- HER-MES (NCT03828539)
- Testing
- Erenumab, Topiramate
- Where
- 79 sites in Germany
- Volunteers
- 777 people
- Sponsor
- Novartis Pharmaceuticals
Migraine
A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants
This first in-human (FIH) study of UB-313, an anti-calcitonin gene-related peptide based immunotherapeutic candidate, is designed to assess the safety, tolerability, and immunogenicity of 4 selected UB-313 dose regimens in…
- Trial name
- NCT05477095
- Testing
- UB-313
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Vaxxinity, Inc.
Migraine
A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis
This study will provide additional efficacy data for rizatriptan when used for an acute migraine attack in patients already taking topiramate for migraine prophylaxis.
- Trial name
- NCT00812006
- Testing
- rizatriptan benzoate
- Volunteers
- 108 people
- Sponsor
- Organon and Co
Migraine Disorders
Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Study to understand the effects of migraine treatments on blood pressure in participants with migraine. The primary hypothesis is that the effect on semi-recumbent mean arterial pressure following the coadministration of…
- Trial name
- NCT00701389
- Testing
- telcagepant potassium, sumatriptan
- Volunteers
- 24 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as Galcanezumab in Japanese participants with migraine.
- Trial name
- NCT02959190
- Testing
- Galcanezumab
- Where
- 44 sites in Japan
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Migraine
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine
The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in Japanese participants with episodic migraine.
- Trial name
- NCT02959177
- Testing
- Galcanezumab
- Where
- 47 sites in Japan
- Volunteers
- 459 people
- Sponsor
- Eli Lilly and Company
Chronic Migraine
Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine
The purpose of this study is to determine if milnacipran taken twice daily is effective in reduction of headache pain.
- Trial name
- NCT01393522
- Testing
- Milnacipran
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Timothy Smith
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Headache Disorders, Primary, Migraine With Aura
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including…
- Conditions
- Headache Disorders, Primary, Migraine With Aura, Migraine Without Aura, Tension-Type Headache
- Trial name
- PRESTO (NCT02115269)
- Where
- 30 sites in Kazakhstan, Ukraine
- Volunteers
- 759 people
- Sponsor
- Abbott
Vestibular Migraine
Galcanezumab for Vestibular Migraine
Vestibular migraine (VM) has been recognized a distinct subtype of migraine that causes dizziness as the predominant symptom. Criteria for diagnosis have been adopted by the Barany Society.
- Trial name
- NCT04417361
- Testing
- Galcanezumab Prefilled Syringe
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Migraine
Imaging the Migraine Brain Pre- and Post-Erenumab
Researchers are trying to determine if there is a difference between brain images of subjects that do respond to treatment with erenumab and subjects who do not respond to treatment with erenumab using Magnetic Resonance Imaging…
- Trial name
- NCT03773562
- Testing
- Erenumab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Migraine
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine
The study is being conducted to evaluate two doses of TEV-48125 in adult patients with episodic migraine
- Trial name
- NCT02629861
- Testing
- Fremanezumab
- Where
- 275 sites in United States, Canada and 7 more
- Volunteers
- 875 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.